News
Oma Fertility announces partnership to “set a new standard” for IVF
The partnership is hoped to help the US provider improve IVF success rates and reach more patients struggling with infertility
The US fertility clinic Oma has announced new strategic collaborations with agency partners to integrate technology in fertility care.
Oma aims to help aspiring parents conceive by bringing AI and robotics to in-house fertility treatments and collaborating with third parties such as surrogate agencies and egg and sperm banks.
As part of a new partnership, the fertility provider will collaborate with Fuseproject, DDB Chicago, Jack Taylor and Toast Media Group to accelerate growth and reach more patients in need of treatment.
“Strategic partners are an important part of the Oma Fertility growth strategy, and we are pleased to add Fuseproject, DDB, Jack Taylor and Toast Media Group into our ecosystem,” said Seth Goldberg, Oma Fertility chief marketing officer.
“Although 19 per cent of women and 10 per cent of men struggle with infertility, the fertility category is often viewed as unwelcoming and difficult to navigate.
“Oma is transforming and modernising the fertility industry and we look forward to our new partners helping us bring our brand to life.”
The provider seeks to improve IVF outcomes with its technology called Oma Sperm InSight that aims to help embryologists identify the most promising sperm cell to pair with an egg in IVF.
The company opened its first clinic in Santa Barbara, California in 2021 and expanded in five other cities, with plans to extend nationally in 2023.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Diagnosis2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







Pingback: URL
Pingback: คาสิโนสด ส่งตรงจากคาสิโนแบบเรียลไทม์
Pingback: สล็อตวอเลท เติมเงินเว็บตรง AUTO ไม่มีขั้นต่ำ
Pingback: escape from tarkov hacks
Pingback: bangkok tattoo
Pingback: ทางเข้าpg